-
1
-
-
0034020556
-
Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function
-
Veronese L, Rautaureau J, Sadler BM et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 2000; 44: 821-6.
-
(2000)
Antimicrob Agents Chemother
, vol.44
, pp. 821-826
-
-
Veronese, L.1
Rautaureau, J.2
Sadler, B.M.3
-
2
-
-
0032741963
-
Saquinavir therapy in patients with advanced HIV infection and liver cirrhosis
-
Tachikawa N, Yoshizawa S, Kikuchi Y et al. Saquinavir therapy in patients with advanced HIV infection and liver cirrhosis. Jpn J Infect Dis 1999; 52: 177-8.
-
(1999)
Jpn J Infect Dis
, vol.52
, pp. 177-178
-
-
Tachikawa, N.1
Yoshizawa, S.2
Kikuchi, Y.3
-
3
-
-
19944432901
-
Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects
-
Regazzi M, Maserati R, Villani P et al. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrob Agents Chemother 2005; 49: 643-9.
-
(2005)
Antimicrob Agents Chemother
, vol.49
, pp. 643-649
-
-
Regazzi, M.1
Maserati, R.2
Villani, P.3
-
4
-
-
34548797690
-
Fosamprenavir(FPV)/ ritonavir(rtv) dose adjustment for patients with mild and moderate hepatic impairment (HI) (APV10017)
-
Abstract 1
-
Mallolas J, Perez-Elias MJ, Ortega E et al. Fosamprenavir(FPV)/ ritonavir(rtv) dose adjustment for patients with mild and moderate hepatic impairment (HI) (APV10017). In: Abstracts of the Eighth International Workshop on Clinical Pharmacology of HIV Therapy, Budaest, Hungary, 2007. Abstract 1.
-
Abstracts of the Eighth International Workshop on Clinical Pharmacology of HIV Therapy, Budaest, Hungary, 2007
-
-
Mallolas, J.1
Perez-Elias, M.J.2
Ortega, E.3
-
5
-
-
0034606721
-
Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
-
Sulkowski MS, Thomas DL, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
-
(2000)
JAMA
, vol.283
, pp. 74-80
-
-
Sulkowski, M.S.1
Thomas, D.L.2
Chaisson, R.E.3
-
6
-
-
0032945886
-
Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography
-
Hugen PW, Verweij-van Wissen CP, Burger DM et al. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999; 727: 139-49.
-
(1999)
J Chromatogr B Biomed Sci Appl
, vol.727
, pp. 139-149
-
-
Hugen, P.W.1
Verweij-van Wissen, C.P.2
Burger, D.M.3
-
7
-
-
0034469255
-
Bioanalylicall method validation - a revisit with a decade of progress
-
Shah VP, Midha KK, Findlay JWA et al. Bioanalylicall method validation - a revisit with a decade of progress. Pharm Res 2000; 17: 1551-7.
-
(2000)
Pharm Res
, vol.17
, pp. 1551-1557
-
-
Shah, V.P.1
Midha, K.K.2
Findlay, J.W.A.3
-
8
-
-
9144240623
-
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients
-
Wood R, Arasteh K, Stellbrink HJ et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2004; 48: 116-23.
-
(2004)
Antimicrob Agents Chemother
, vol.48
, pp. 116-123
-
-
Wood, R.1
Arasteh, K.2
Stellbrink, H.J.3
-
9
-
-
0035115820
-
1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor
-
1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 2001; 45 852-6.
-
(2001)
Antimicrob Agents Chemother
, vol.45
, pp. 852-856
-
-
Sadler, B.M.1
Gillotin, C.2
Lou, Y.3
-
10
-
-
34548783469
-
-
Norvir (ritonavir, Prescribing information USA, North Chicago, IL: Abbott Laboratories
-
Norvir (ritonavir). Prescribing information (USA). North Chicago, IL: Abbott Laboratories.
-
-
-
-
11
-
-
33644645264
-
Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir
-
Shelton MJ, Wire MB, Lou Y et al. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob Agents Chem 2006; 50: 928-34.
-
(2006)
Antimicrob Agents Chem
, vol.50
, pp. 928-934
-
-
Shelton, M.J.1
Wire, M.B.2
Lou, Y.3
-
12
-
-
34548767874
-
Ritonavir pharmacokinetics in HIV-infected patients with underlying hepatic disease
-
Abstract 359. Foundation for Retrovirology and Human Health, Alexandria, VA, USA
-
Cameron DW, Valdes J, Garber G et al. Ritonavir pharmacokinetics in HIV-infected patients with underlying hepatic disease. In: Abstracts of the Fifth Conference on Retrovirus and Opportunistic Infections, Chicago, IL, 1998 Abstract 359. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
-
Abstracts of the Fifth Conference on Retrovirus and Opportunistic Infections, Chicago, IL, 1998
-
-
Cameron, D.W.1
Valdes, J.2
Garber, G.3
-
13
-
-
34548751973
-
-
Peng J, Bertz R, Hsu A et al. Evaluation of single and multiple dose pharmacokinetics of ritonavir in subjects with mild or moderate hepatic insufficiency. In: Abstracts of the Fourth International Workshop on Clinical Pharmacology of HIV Therapy, Cannes, France, 2003 Abstract 16, p.3.7.
-
Peng J, Bertz R, Hsu A et al. Evaluation of single and multiple dose pharmacokinetics of ritonavir in subjects with mild or moderate hepatic insufficiency. In: Abstracts of the Fourth International Workshop on Clinical Pharmacology of HIV Therapy, Cannes, France, 2003 Abstract 16, p.3.7.
-
-
-
-
14
-
-
0036294598
-
Effect of interferon α-ribavirin biotherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransterase-2 activities in patients with chronic active hepatitis C
-
Becquerhont L, Chazouilleres O, Serfaty L et al. Effect of interferon α-ribavirin biotherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransterase-2 activities in patients with chronic active hepatitis C. Clin Pharm Ther 2002; 71: 488-95.
-
(2002)
Clin Pharm Ther
, vol.71
, pp. 488-495
-
-
Becquerhont, L.1
Chazouilleres, O.2
Serfaty, L.3
-
15
-
-
32944457844
-
Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment
-
Peng JZ, Pulido F, Causemaker SJ et al. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol 2006; 46: 265-74.
-
(2006)
J Clin Pharmacol
, vol.46
, pp. 265-274
-
-
Peng, J.Z.1
Pulido, F.2
Causemaker, S.J.3
-
16
-
-
10244222704
-
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir
-
Sulkowski MS, Mehta SH, Chaisson RE et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18: 2277-84.
-
(2004)
AIDS
, vol.18
, pp. 2277-2284
-
-
Sulkowski, M.S.1
Mehta, S.H.2
Chaisson, R.E.3
-
17
-
-
27944467897
-
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
-
Mocroft A, Soriano V, Rockstroh J et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19: 2117-25.
-
(2005)
AIDS
, vol.19
, pp. 2117-2125
-
-
Mocroft, A.1
Soriano, V.2
Rockstroh, J.3
-
18
-
-
14744286600
-
Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients
-
Canta F, Marrone R, Bonora et al. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. J Antimicrob Chemother 2005; 55: 280-1.
-
(2005)
J Antimicrob Chemother
, vol.55
, pp. 280-281
-
-
Canta, F.1
Marrone, R.2
Bonora3
|